Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark D Pescovitz

Showing results (31-40 of 63) with videos related to

Pageof 7
Sort By:
Transplantation|December 23, 2004
Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipientsRichard B Freeman, Carlos Paya, Mark D Pescovitz, et al.
Human Immunology|September 1, 2004
Pronase treatment facilitates alloantibody flow cytometric and cytotoxic crossmatching in the presence of rituximabChristopher M Bearden, Avinash Agarwal, Benita K Book, et al.
Clinical Transplantation|February 6, 2004
Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantationMark D Pescovitz, Ginny Bumgardner, Robert S Gaston, et al.
Antiviral Therapy|August 26, 2009
Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovirGuy Boivin, Nathalie Goyette, Halvor Rollag, et al.
Transplantation|October 30, 2012
Treatment of cytomegalovirus disease in solid organ transplant recipients: markers of inflammation as predictors of outcomeHalvor Rollag, Anders Asberg, Thor Ueland, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|April 16, 2003
The addition of sirolimus to cyclosporine and steroids inhibits the anti-equine antibody response in renal transplant recipients treated with antithymocyte globulinMark D Pescovitz, Benita K Book, Sharon Henson, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|September 16, 2005
A surveillance study of adenovirus infection in adult solid organ transplant recipientsAtul Humar, Deepali Kumar, Tony Mazzulli, et al.
Journal of Transplantation|August 31, 2012
A prospective, multinational pharmacoepidemiological study of clinical conversion to sirolimus immunosuppression after renal transplantationBertram L Kasiske, Bjorn Nashan, Maria Del Carmen Rial, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|March 17, 2004
Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D+/R- solid organ transplant recipientsAtul Humar, Carlos Paya, Mark D Pescovitz, et al.
Plos One|April 18, 2013
Characterization of cytomegalovirus disease in solid organ transplant recipients by markers of inflammation in plasmaHalvor Rollag, Thor Ueland, Anders Asberg, et al.
Pageof 7

Showing results (31-40 of 63) with videos related to

Sort By:
Pageof 7
Transplantation|December 23, 2004
Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipientsRichard B Freeman, Carlos Paya, Mark D Pescovitz, et al.
Human Immunology|September 1, 2004
Pronase treatment facilitates alloantibody flow cytometric and cytotoxic crossmatching in the presence of rituximabChristopher M Bearden, Avinash Agarwal, Benita K Book, et al.
Clinical Transplantation|February 6, 2004
Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantationMark D Pescovitz, Ginny Bumgardner, Robert S Gaston, et al.
Antiviral Therapy|August 26, 2009
Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovirGuy Boivin, Nathalie Goyette, Halvor Rollag, et al.
Transplantation|October 30, 2012
Treatment of cytomegalovirus disease in solid organ transplant recipients: markers of inflammation as predictors of outcomeHalvor Rollag, Anders Asberg, Thor Ueland, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|April 16, 2003
The addition of sirolimus to cyclosporine and steroids inhibits the anti-equine antibody response in renal transplant recipients treated with antithymocyte globulinMark D Pescovitz, Benita K Book, Sharon Henson, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|September 16, 2005
A surveillance study of adenovirus infection in adult solid organ transplant recipientsAtul Humar, Deepali Kumar, Tony Mazzulli, et al.
Journal of Transplantation|August 31, 2012
A prospective, multinational pharmacoepidemiological study of clinical conversion to sirolimus immunosuppression after renal transplantationBertram L Kasiske, Bjorn Nashan, Maria Del Carmen Rial, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|March 17, 2004
Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D+/R- solid organ transplant recipientsAtul Humar, Carlos Paya, Mark D Pescovitz, et al.
Plos One|April 18, 2013
Characterization of cytomegalovirus disease in solid organ transplant recipients by markers of inflammation in plasmaHalvor Rollag, Thor Ueland, Anders Asberg, et al.
Pageof 7